Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Abroad (travel likely)RecruitingPHASE2
Conditions
Non-small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study leads
Melina Marmarelis, MD
Principal Investigator
Abramson Cancer Center at Penn Medicine